vaccin
continu
offer
key
line
protect
rang
infecti
diseas
howev
rang
vaccin
current
avail
limit
one
key
consider
develop
vaccin
riskversusbenefi
environ
perceiv
low
risk
benefi
vaccin
may
recognis
address
move
toward
use
subunitbas
vaccin
offer
low
sideeffect
profi
le
gener
weakli
immunogen
compens
develop
effect
adjuv
nanotechnolog
offer
key
attribut
fi
eld
abil
nanoparticul
incorpor
protect
antigen
rapid
degrad
combin
potenti
effect
deliv
antigen
appropri
cell
within
immun
system
characterist
exploit
develop
new
adjuv
chapter
outlin
applic
nanosystem
vaccin
formul
consid
mechan
action
behind
rang
formul
infecti
diseas
remain
among
lead
caus
death
worldwid
vaccin
offer
one
effect
strategi
global
healthcar
address
howev
ongo
need
develop
new
effect
vaccin
formul
offer
protect
new
emerg
diseas
eg
sever
acut
respiratori
syndrom
sar
viru
coronaviru
human
immunodefi
cienci
viru
hiv
reemerg
old
andor
persist
infecti
diseas
eg
tuberculosi
malaria
foodborn
infect
alreadi
seen
within
book
nanotechnolog
play
key
role
mani
pharmaceut
applic
vaccin
except
applic
nanosci
vaccin
formul
offer
potenti
enhanc
effi
caci
vaccin
promot
enhanc
protect
effect
deliveri
antigen
effect
exploit
nanotechnolog
vaccin
develop
must
fi
rst
consid
possibl
mechan
support
effect
immunis
immun
system
compris
mani
cellular
humour
compon
protect
host
diseas
term
includ
infect
autoimmun
syndrom
injuri
mutat
host
acquir
abil
evolv
environ
classic
exampl
gut
wherebi
commens
microb
live
harmoni
host
immun
system
two
main
function
recognis
invad
pathogen
activ
mechan
destroy
pathogen
control
termin
innat
immun
respons
readi
react
quickli
fig
compon
innat
immun
present
onset
infect
constitut
set
diseaseresist
mechan
specifi
c
particular
pathogen
mechan
includ
cellular
molecular
compon
recognis
class
molecul
differ
frequent
encount
pathogen
goldsbi
et
al
phagocyt
cell
neutrophil
macrophag
addit
pattern
recognit
receptor
nk
cell
complement
varieti
antimicrobi
compound
synthesis
host
play
import
role
innat
immun
goldsbi
et
al
adapt
immun
respons
fig
made
b
lymphocyt
uniqu
receptor
specifi
c
variou
microbi
antigen
sudhakar
subramani
contrast
receptor
innat
immun
system
mani
differ
type
specifi
c
particular
pathogen
parham
antigenspecifi
c
receptor
encod
gene
gener
complex
process
gene
rearrang
occur
cours
lymphocyt
develop
b
lymphocyt
contain
uniqu
antigen
receptor
allow
larg
divers
popul
cell
capabl
recognis
wide
spectrum
pathogen
term
lymphocyt
repertoir
sudhakar
subramani
respons
infect
lymphocytesbear
receptor
specifi
c
pathogen
select
particip
immun
respons
prolifer
differenti
cell
term
clonal
select
expans
gener
larg
popul
specifi
c
effector
cell
assist
futur
invas
pathogen
lymphocyt
persist
bodi
provid
longterm
immunolog
memori
thu
result
faster
stronger
respons
parham
therefor
immun
system
develop
offer
wide
rang
protectionhowev
one
issu
infect
bodi
must
abl
respond
quickli
vigor
enough
provid
appropri
protect
without
individu
suffer
potenti
lethal
consequ
infect
address
vaccin
develop
vaccin
defi
ned
prepar
nonselfcel
rapidli
attack
innat
immun
system
key
player
innat
system
neutrophil
macrophag
pattern
recognit
receptor
nk
cell
complement
desir
end
result
destruct
foreign
substanc
nonselfcel
b
adapt
immun
respons
major
player
respons
b
lymphocyt
lymphocyt
nk
cell
desir
end
result
destruct
nonselfcel
complex
tightli
orchestr
seri
event
base
bingham
made
pathogen
use
vaccin
provid
protect
immun
infect
pathogen
parham
ultim
goal
vaccin
develop
longliv
immunolog
protect
wherebi
fi
rst
encount
pathogen
rememb
recognis
immun
system
therefor
immun
system
gener
rapid
protect
respons
infect
origin
vaccin
lie
smallpox
diseas
ravag
part
world
initi
descript
smallpox
stem
earli
bc
text
origin
china
smallpox
known
spread
rapidli
result
disfi
gurement
blind
death
also
known
smallpox
infecti
earli
report
date
bc
describ
survivor
smallpox
use
treat
infect
process
known
inocul
gross
sepkowitz
mani
hundr
year
concept
inocul
began
take
form
involv
small
swab
infecti
materi
otherwis
known
pu
place
skin
noninfect
person
member
english
royal
famili
success
immunis
smallpox
use
method
riedel
howev
work
edward
jenner
born
gloucestershir
uk
support
develop
vaccin
jenner
overhear
young
dairymaid
claim
may
never
smallpox
cowpox
decid
investig
jenner
success
inocul
young
boy
infecti
materi
dairymaid
cowpox
lesion
month
later
expos
boy
smallpox
diseas
result
begin
term
vaccin
tradit
organis
vaccin
group
four
categori
kill
attenu
toxoid
subunit
vaccin
live
attenu
vaccin
consist
live
microbi
agent
mutat
reduc
abil
grow
human
cell
longer
pathogen
human
parham
microorgan
still
abl
infect
target
cell
howev
infect
ineffi
cient
mild
limit
replic
microorgan
vaccin
produc
manner
includ
bacillu
bcg
measl
mump
yellow
fever
vaccin
rubella
combin
vaccin
mmr
vaccin
gener
capabl
stimul
humour
cellmedi
immun
respons
howev
risk
revers
virul
type
vaccin
consid
safe
use
immunocompromis
individu
inactiv
vaccin
inactiv
vaccin
consist
microorgan
virus
treat
eg
heat
chemic
formaldehyd
therebi
remov
abil
infecti
retain
immunogen
offer
advantag
term
safeti
vaccin
gener
less
effect
live
attenu
vaccin
usual
stimul
humour
immun
often
requir
booster
dose
exampl
vaccin
includ
trival
inactiv
infl
uenza
vaccin
cholera
hepat
vaccin
microorgan
produc
toxic
compound
respons
caus
diseas
ie
tetanu
toxin
diphtheria
toxin
toxoid
inactiv
form
toxic
compound
addit
success
vaccin
right
toxoid
may
also
use
increas
immunogen
vaccin
haemophilu
infl
uenza
type
b
hib
contain
polysaccharid
unit
viru
conjug
diphtheria
tetanu
toxin
subunit
vaccin
initi
strong
immun
respons
use
small
part
organ
could
includ
gene
genom
recombin
dna
technolog
greatli
facilit
develop
vaccin
process
foreign
gene
introduc
yeast
bacteria
express
system
allow
product
larg
quantiti
antigen
purifi
ed
use
vaccin
arvin
greenberg
principl
benefi
ts
subunit
vaccin
inabl
revert
pathogen
form
decreas
toxic
reproduc
product
improv
antigen
specifi
citi
howev
immun
respons
induc
vaccin
shortliv
thu
sever
boost
requir
achiev
protect
hepat
b
viru
exampl
surfac
protein
viru
use
gener
subunit
vaccin
highlight
tabl
clear
rule
type
vaccin
recombinantkilledattenu
etc
may
superior
certain
diseas
certainli
present
aim
vaccinologist
focu
safeti
includ
low
toxic
prevent
revers
virul
howev
immunogen
obvious
play
major
role
regard
smallpox
live
attenu
composit
vaccin
led
success
erad
diseas
numer
fried
mbow
et
al
factor
certainli
contribut
includ
lack
anim
reservoir
nonzoonot
diseas
stabil
vaccin
formul
clear
diseas
symptom
howev
interest
note
side
effect
vaccin
also
suffi
cientli
bad
vaccin
campaign
unit
state
halt
year
prior
declar
world
free
smallpox
kennedi
et
al
therefor
even
vaccin
ever
led
erad
diseas
fault
probabl
smallpox
vaccin
still
requir
today
would
use
would
fail
clinic
trial
fi
rst
market
subunit
vaccin
avail
unit
state
protect
hepat
b
hilleman
therefor
term
arriv
onto
vaccin
market
subunit
vaccin
latecom
develop
rather
discoveri
hinder
poor
immunogen
profi
le
howev
import
advantag
attenu
kill
vaccin
chanc
revers
virul
form
subunit
vaccin
base
sole
antigen
epitop
origin
deriv
virul
organ
total
loss
molecul
would
typic
alert
host
danger
natur
pathogen
addit
loss
particul
natur
appear
downfal
subunit
vaccinesthey
lack
suffi
cient
resembl
pathogen
therefor
effort
improv
immun
respons
subunit
antigen
adjuv
includ
formul
adjuv
whose
name
stem
latin
adjuvar
mean
aid
defi
ned
substanc
use
combin
specifi
c
antigen
produc
robust
immun
respons
compar
antigen
alon
gupta
et
al
vogel
adjuv
come
wide
rang
shape
size
even
though
document
adjuv
exist
nearli
year
still
univers
approv
group
system
figur
summaris
current
suggest
mechan
adjuv
action
one
fi
rst
paper
publish
ramon
describ
adjuv
effect
rang
compound
includ
tapioca
agar
starch
oil
ramon
follow
use
inorgan
compound
includ
aluminium
phosphat
aluminium
hydroxid
document
glenni
et
al
aluminiumbas
compound
becam
fi
rst
licens
adjuv
commerci
vaccin
late
aluminiumbas
compound
remain
uslicens
adjuv
europ
wider
scope
adjuv
recognis
eg
tabl
howev
adjuv
develop
bench
market
vaccin
slow
fi
rst
nonaluminium
salt
adjuv
licens
less
year
ago
mbow
et
al
ohagan
gregorio
slow
output
lack
success
licens
due
numer
reason
includ
poor
scaleup
infl
exibl
regard
scope
antigen
administ
ohagan
gregorio
howev
vari
immunis
abil
differ
vaccin
adjuv
bear
remark
similar
structur
composit
consid
requir
hardli
surpris
reason
adjuv
licens
individu
vaccin
oppos
consid
separ
entiti
fig
alum
collect
term
often
use
refer
group
aluminium
salt
includ
aluminium
hydroxid
aluminium
phosphat
aluminium
potassium
sulphat
correct
term
group
adjuv
aluminium
salt
alum
correctli
refer
aluminium
potassium
sulphat
marrack
et
al
widespread
use
aluminium
salt
vaccin
adjuv
due
combin
abil
gener
speak
improv
vaccin
immun
respons
well
provid
excel
safeti
profi
le
occasion
local
reaction
includ
infl
ammat
erythroma
subcutan
nodul
allerg
reaction
report
number
peopl
vaccin
consid
aluminium
salt
exemplari
adjuv
clement
griffi
th
major
downfal
aluminium
salt
polaris
immun
respons
activ
predomin
activ
immun
ie
aluminium
salt
ideal
adjuv
vaccin
requir
increas
costimulatori
molecul
adjuv
antigen
associ
strong
humor
immun
high
level
antibodi
cytokin
exampl
includ
vaccin
extracellular
pathogen
parasit
diseas
eg
leishmaniasi
toxoidproduc
pathogen
eg
diphtheria
tetanu
among
method
use
mediat
balanc
one
involv
combin
aluminium
salt
adjuv
known
strong
stimul
respons
exampl
includ
aluminium
hydroxid
combin
cation
liposom
agger
et
al
monophosphoryl
lipid
mpl
latter
licens
adjuv
glaxosmithklin
gsk
biolog
recent
mechan
aluminium
salt
adjuv
act
start
uncov
challeng
previou
dogma
adjuvant
pathogen
endocytos
activ
tlr
via
pathogenassoci
molecular
pattern
pamp
result
initi
intracellular
event
includ
releas
alarmin
activ
adapt
protein
respect
ii
signal
pathway
becom
activ
lead
cleavag
activ
transcript
factor
product
proinfl
ammatori
cytokin
produc
pro
inhibitori
domain
iii
endogen
atp
act
alarmin
activ
receptor
lead
potassium
effl
ux
cell
iv
combin
potassium
effl
ux
tlr
activ
lead
cleavag
activ
caspas
compon
infl
ammasom
abl
cleav
prodomain
cytokin
v
cell
prolifer
proinflammatori
cytokin
simpli
due
longer
retent
antigen
inject
site
also
known
depoteffect
marrack
et
al
import
mechan
antigen
associ
aluminium
adjuv
remain
debat
eg
morefi
eld
et
al
howev
clear
aluminium
salt
prevent
rapid
remov
degrad
antigen
normal
seen
upon
inject
free
antigen
wide
rang
literatur
mechan
aluminium
action
indepth
review
see
brewer
marrack
et
al
strongli
suggest
role
infl
ammasom
uric
acid
releas
upon
local
tissu
damag
marrack
et
al
ohagan
gregorio
briefl
inject
aluminium
salt
known
caus
tissu
damag
cell
death
releas
alarmin
endogen
uric
acid
infi
ltration
neutrophil
infl
ammatori
mediat
uric
acid
capabl
activ
caspas
compon
infl
ammasom
subsequ
cleav
prounit
activ
form
kool
et
al
see
refer
within
kennedi
et
al
mariathasan
martinon
et
al
moni
et
al
gener
speak
adjuv
divid
group
depend
physic
properti
inorgan
salt
liposom
oil
water
ow
emuls
surfact
etc
classifi
cation
pose
problem
method
adjuv
act
unknown
therefor
help
elimin
identifi
potenti
nanosystem
futur
adjuv
candid
anoth
classifi
cation
becom
complex
time
propos
ohagen
de
gregorio
wherebi
adjuv
class
fi
rstor
secondgener
adjuv
system
fi
rstgener
adjuv
refer
one
tradit
substanc
normal
compos
one
immunostimulatori
compound
includ
aluminium
salt
liposom
among
other
addit
immunostimulatori
compound
exist
fi
rstgener
adjuv
result
secondgener
adjuv
aforement
adjuv
system
gsk
biolog
intercel
austria
iscom
possibl
exist
extend
system
thirdgener
adjuv
fourth
fi
fth
etc
system
becom
increasingli
awkward
give
indic
adjuv
may
work
virgil
schijn
propos
system
wherebi
adjuv
divid
group
depend
method
immunostimulatori
action
schijn
fi
group
suggest
possibl
mechan
may
deduc
futur
addit
diffi
culti
classifi
cation
one
adjuv
one
mode
action
final
possibl
simplest
involv
classifi
cation
system
base
whether
adjuv
work
via
tlr
mosca
et
al
instanc
two
group
exist
tlrdepend
tlrindepend
howev
adjuv
contain
two
immunogen
compon
gsk
adjuv
contain
aluminium
hydroxid
mpl
may
act
via
tlrdepend
tlrindepend
mechan
complic
matter
purpos
identifi
mechan
action
present
futur
adjuv
classifi
cation
system
schijn
appropri
basi
adjuv
work
describ
herein
accord
schijn
classifi
cation
fi
method
adjuv
may
immunostimulatori
highlight
fig
method
provid
ideal
way
explain
immun
system
relev
system
deliveri
vaccin
upon
parent
vaccin
deliveri
localis
tissu
damag
result
physic
insert
needl
vaccin
compon
tissu
milieu
cell
inevit
ruptur
releas
intracellular
content
includ
mitochondria
uric
acid
heat
shock
protein
hsp
term
alarmin
bianchi
alarmin
hostderiv
substanc
releas
upon
nonintent
cell
death
contrast
apoptosi
unsurprisingli
signal
host
problem
tissu
destruct
stress
consid
fi
rst
mechan
adjuv
action
shi
et
al
term
danger
signal
refer
danger
model
origin
describ
matzing
danger
model
assum
host
differenti
harmless
harm
oppos
self
nonself
later
model
origin
describ
metchnikoff
thoroughli
review
janeway
overlap
danger
model
concept
signal
second
class
adjuv
act
signal
includ
alarmin
respect
adjuv
composit
formul
signal
group
princip
includ
exogen
pathogenassoci
molecular
pattern
pamp
importantli
signal
concept
physic
bind
alarmin
pamp
collect
term
dangerassoci
molecular
pattern
damp
bianchi
pathogen
recognit
receptor
prr
result
intracellular
signal
cascad
result
activ
cell
see
fig
schemat
damp
tlr
prr
constitut
express
within
cell
innat
immun
system
schijn
includ
among
other
tlr
infl
ammasom
integrin
ctype
lectin
antibodi
fc
receptor
specifi
c
signal
cascad
initi
dampprr
interact
discuss
later
result
action
includ
product
proinfl
ammatori
cytokin
chemokin
costimulatori
molecul
requir
product
activ
cell
upon
antigen
present
fact
antigen
present
without
simultan
costimulatori
molecul
interact
shown
lead
toler
costimulatori
molecul
consequ
import
success
cell
activ
express
constitut
dc
express
apc
includ
macrophag
b
cell
upon
activ
adjuv
abl
activ
macrophag
b
cell
induc
express
abl
upregul
express
said
marker
dc
group
third
adjuvant
categori
recombin
signal
principl
adjuv
group
cytokin
consid
endogen
adjuv
also
administ
vaccin
experiment
see
boyaka
mcghee
egan
israel
heath
playfair
review
articl
well
tlrsignal
adjuv
fi
nal
two
adjuvant
categori
relat
physic
structur
adjuv
physic
localis
vivo
discuss
previous
much
divers
structur
adjuv
although
mani
base
emuls
vesicular
structur
benefi
ts
vesicular
structur
twofold
fi
rstli
use
carri
antigen
either
entrap
adsorpt
secondli
vesicl
natur
occur
appropri
size
structur
endocytos
cell
depend
composit
size
make
ideal
intracellular
deliveri
system
paradigm
assist
antigen
uptak
fourth
adjuvant
categori
princip
concern
liposom
nanoparticl
microspher
virosom
emuls
iscom
abl
packag
antigen
deliveri
vehicl
fi
nal
concept
idea
antigen
held
inject
site
long
period
time
result
lengthi
present
antigen
innat
immun
cell
known
depoteffect
refer
localis
antigen
without
adjuv
inject
site
lymphoid
organ
although
increas
present
antigen
lymphoid
organ
may
direct
consequ
depoteffect
often
desir
effect
depoteffect
therefor
depend
numer
factor
rout
inject
tissu
found
inject
site
characterist
associ
formul
viscos
particul
size
analysi
differ
type
adjuv
clear
still
mani
overlap
group
howev
system
devis
schijn
help
defi
ne
mechan
adjuv
work
mind
possibl
envisag
perfect
adjuv
would
work
firstli
must
contain
suffi
cient
amount
pamp
alert
immun
system
danger
without
caus
hyperimmunostimul
may
result
anaphylact
shock
local
tissu
damag
excess
infl
ammatori
mediat
pamp
pamp
without
suffi
cient
toxic
may
stimul
suffi
cient
product
proinfl
ammatori
molecul
chemokin
vital
alert
circul
apc
may
certain
degre
local
tissu
damag
also
benefici
allow
releas
alarmin
promot
apc
infl
ux
inject
site
shi
et
al
adjuv
also
ideal
stay
associ
antigen
uptaken
apc
immun
system
make
collect
associ
compon
free
antigen
form
nucleic
materi
small
peptid
antigen
rapidli
degrad
extracellular
enzym
mani
subunit
protein
vaccin
antigen
immunogen
inert
protein
peptid
antigen
undergo
rapid
remov
via
circulatori
lymphat
system
without
danger
signal
attach
protein
may
simpli
remov
antigen
uptak
present
occur
given
key
characterist
outlin
surpris
nanosystem
extens
consid
exploit
potenti
vaccin
adjuv
wide
rang
nanomateri
consid
exampl
includ
nanoparticl
virosom
immunestimul
complex
iscom
liposom
bilosom
among
other
associ
antigen
nanosystem
antigen
protect
extracellular
milieu
therebi
limit
peptideprotein
nucleic
antigen
breakdown
enzym
well
prevent
rapid
remov
small
compound
mononuclear
phagocyt
system
mp
immunolog
role
adjuv
properti
liposom
fi
rst
identifi
ed
allison
gregoriadi
abil
neg
charg
liposom
prepar
inclus
dicetyl
phosphat
deliv
potenti
immun
respons
diphtheria
toxoid
dt
demonstr
sinc
immunolog
adjuvant
liposom
well
recognis
liposom
extens
investig
potenti
vaccin
adjuv
year
number
antigen
includ
eg
tetanu
toxoid
davi
gregoriadi
leishmania
major
antigen
kahl
et
al
hepat
b
surfac
antigen
brunei
et
al
dna
vaccin
perri
et
al
perri
et
al
tuberculosi
vaccin
davidsen
et
al
smith
korsholm
et
al
liposomalbas
vaccin
ie
virosom
licens
human
use
ie
infl
exal
vaccin
infl
uenza
yet
wealth
research
date
base
improv
immun
respons
aid
liposom
gener
attent
given
abil
formul
effect
deliv
vaccin
enhanc
protect
apc
uptak
antigen
howev
given
current
understand
adjuv
recent
focu
turn
deliveri
attribut
also
immunomodul
therefor
research
focuss
combin
deliveri
attribut
liposom
adjuv
properti
inclus
immunomodul
molecul
exampl
olsen
et
al
show
increas
induct
protect
immun
tuberculosi
isol
protein
antigen
found
mycobacteri
cultur
fi
ltrate
incorpor
within
liposom
vesicl
combin
dimethyldioctadecylammonium
dda
hydrat
aqueou
environ
cation
lipid
selfassembl
close
bilay
olsen
et
al
yet
identifi
ed
protein
possess
low
inher
immunogen
inject
alon
andersen
author
reach
conclus
order
immun
protect
remain
high
extend
period
depot
must
form
inject
site
dda
holten
andersen
et
al
olsen
et
al
holtenandersen
cowork
conclud
dda
may
act
increas
antigen
immunostimul
uptak
apc
form
depot
immunostimulatori
properti
cation
lipid
origin
document
screen
studi
gall
within
studi
wide
rang
compound
investig
abil
adjuv
diphtheria
tetanu
toxoid
guinea
pig
compound
includ
nonion
anion
cation
surfaceact
agent
amin
guanidin
benzamidin
thiourea
thiosemicarbazid
thiosemicarbazon
thiouronium
variou
nitrogen
base
regard
group
surfaceact
agent
commonli
term
surfact
gall
observ
increas
adjuvant
express
cation
quaternari
ammonium
head
group
long
alkyl
chain
gall
within
group
dda
synthet
amphiphil
contain
quaternari
ammonium
group
two
alkyl
chain
form
hydrophob
moieti
two
methyl
group
togeth
ammonium
group
form
polar
head
group
fig
posit
charg
head
group
carri
monoval
counter
ion
typic
bromid
chlorid
due
amphiphil
charact
dda
form
liposom
structur
dispers
aqueou
media
temperatur
geltoliquid
phase
transit
temperatur
davidsen
et
al
dda
known
induc
cellmedi
immun
delayedtyp
hypersensit
snipp
et
al
along
cation
natur
surfact
properti
shown
effect
adjuv
numer
applic
includ
mucos
immunis
klinguer
et
al
gene
deliveri
esposito
et
al
subunit
vaccin
deliveri
lindblad
et
al
brandt
et
al
holtenandersen
et
al
rosenkrand
et
al
mechan
action
behind
adjuv
effect
dda
attribut
posit
surfac
charg
abil
associ
antigen
hilger
et
al
recent
confi
rmed
elabor
use
ovalbumin
ova
model
antigen
stimul
immatur
bone
marrowderiv
dendrit
cell
bmdc
fl
uoresc
label
ova
show
adsorpt
ova
onto
dda
enhanc
cellular
acquisit
antigen
inhibit
activ
cellular
process
ova
stimul
addit
cytochalasin
reduc
cellular
uptak
suggest
activ
actindepend
endocytosi
predomin
uptak
mechan
ddamedi
ova
uptak
associ
function
enhanc
apc
shown
measur
increas
ifngamma
product
cellular
prolifer
purifi
ed
autolog
tcell
transgen
tcell
receptor
recognis
major
histocompat
complex
mhc
class
iirestrict
ovaepitop
prolifer
ifngamma
product
increas
upon
interact
either
murin
bmdc
purifi
ed
bcell
stimul
ova
adsorb
dda
christensen
et
al
recent
studi
replac
dda
neutral
lipid
dspc
demonstr
role
cation
lipid
liposom
adjuv
role
charg
depoteffect
cation
liposom
demonstr
mask
cation
charg
combin
manipul
vesicl
size
antigen
locat
fig
result
laboratori
shown
pegyl
ddabas
liposom
contain
immunostimulatori
lipid
trehalos
diben
polyethylen
glycol
peg
mol
abl
signifi
cantli
inhibit
format
liposom
depot
also
sever
limit
retent
antigen
site
result
faster
drainag
liposom
site
inject
soi
chang
biodistribut
profi
le
refl
ect
immunis
respons
lower
level
antibodi
higher
level
cytokin
found
addit
studi
investig
impact
combin
reduc
vesicl
size
surfac
pegyl
biodistribut
adjuvant
formul
bid
manipul
pharmacokinet
profi
le
adjuv
biodistribut
studi
found
small
unilamellar
vesicl
pegyl
formul
could
infl
uenc
liposom
retent
inject
site
day
higher
level
mol
peg
block
format
depot
promot
clearanc
drain
lymph
node
interestingli
use
peg
small
unilamellar
vesicl
block
format
depot
soi
result
earlier
antibodi
respons
rate
switch
type
cell
respons
bia
suggest
presenc
peg
formul
control
biodistribut
vaccin
also
result
differ
type
interact
innat
immun
cell
kaur
et
al
b
kaur
et
al
b
yet
import
note
effi
caci
dda
may
pure
electrostat
driven
substitut
dda
cation
lipid
includ
n
n
n
dimethylaminoethan
carbomyl
cholesterol
dcchol
fig
propan
dotap
fig
consid
three
cation
liposom
facilit
increas
antigen
present
antigenpres
cell
monocyt
infi
ltration
soi
product
upon
antigen
recal
markedli
higher
dda
dccholbas
liposom
exhibit
longer
retent
profi
le
soi
longterm
retent
slow
releas
liposom
vaccin
antigen
inject
site
henc
appear
favour
stronger
immun
respons
henriksenlacey
et
al
similarli
modifi
cation
hydrophob
backbon
dda
lower
transit
temperatur
lipid
dimethyldioctadecylammonium
bromid
doda
demonstr
antigen
would
readili
dissoci
less
rigid
bilay
dodabas
liposom
liposom
also
rapidli
remov
soi
result
lower
upregul
costimulatori
molecul
adjuvantposit
antigenpres
cell
christensen
et
al
furthermor
adjuv
properti
dda
system
addit
supplement
use
second
lipid
act
immunomodul
tabl
highlight
exampl
immunomodul
incorpor
liposom
deliveri
system
exampl
tdb
fig
synthet
analogu
trehalos
tdm
two
satur
fatti
acid
chain
carbon
behenyl
replac
branch
mycobacteri
mycol
acid
carbon
two
behenyl
chain
link
ester
bond
carbon
number
two
glucopyranos
ring
make
trehalos
head
group
tdb
shown
retain
much
bioactiv
nativ
form
show
less
toxic
result
shorter
fatti
acid
chain
pimm
et
al
old
et
al
combin
dda
tdb
fi
rst
studi
holten
andersen
et
al
use
possibl
tb
antigen
investig
abil
seven
differ
immunostimul
increas
protect
effi
caci
dda
includ
four
mycobacteriaderiv
immunostimul
dda
combin
mpl
andor
tdb
induc
effect
ifngamma
respons
protect
mice
equival
provid
bcg
vaccin
christensen
et
al
adjuv
activ
dda
tdb
combin
also
compar
aluminium
hydroxid
adjuv
approv
human
use
davidsen
et
al
cell
mice
secret
high
level
ifngamma
low
level
respons
dda
tdb
wherea
opposit
pattern
observ
aluminium
hydroxid
davidsen
et
al
christensen
et
al
although
high
level
antibodi
titr
seen
dda
tdbadjuv
vaccin
aluminium
hydroxideadjuv
vaccin
higher
level
antibodi
titr
seen
dda
tdb
davidsen
et
al
agger
et
al
dda
tdb
also
shown
induc
multifunct
tcell
popul
express
sever
cytokin
mainli
tumour
necrosi
factoralpha
tnfalpha
ifngamma
tnfalpha
mice
popul
maintain
least
year
thu
longliv
lindenstrom
et
al
addit
liposom
wide
rang
altern
vesicl
construct
mani
investig
potenti
adjuv
includ
niosom
eg
bailli
et
al
surfact
polym
eg
polymersom
okada
et
al
see
refer
within
mann
et
al
vesicl
incorpor
bile
salt
improv
stabil
eg
bilosom
conach
et
al
viru
compon
eg
virosom
almeida
et
al
name
mani
system
use
altern
phospholipid
circumv
potenti
issu
relat
storag
instabl
cost
eg
syntheticbas
system
other
improv
stabil
within
harsh
biolog
environ
eg
bilosom
polymersom
altern
modul
properti
vesicl
term
immunolog
effi
caci
eg
virosom
term
niosom
use
antigen
deliveri
combin
glycerol
cholesterol
dicetyl
phosphat
dcp
often
employ
bramwel
perri
inclus
dcp
within
system
help
vesicl
format
also
report
enhanc
stabil
due
electrostat
repuls
forc
vesicl
restrict
aggreg
bayindir
yuksel
anion
natur
vesicl
report
aid
uptak
deliv
antigen
via
oral
rout
eldridg
et
al
niosom
prepar
glycerol
cholesterol
dcp
ratio
incorpor
bovin
serum
albumin
brewer
alexand
ovalbumin
brewer
et
al
see
refer
within
bramwel
perri
synthet
peptid
contain
known
tcell
epitop
brewer
et
al
shown
stimul
higher
level
compar
freud
complet
adjuv
vesicl
formul
shown
weak
stimul
addit
adjuv
activ
niosom
wholli
depend
model
antigen
entrap
within
vesicl
mix
free
antigen
preform
vesicl
unabl
elicit
signifi
cant
immun
respons
brewer
alexand
attribut
abil
niosom
retain
antigen
prolong
period
promot
apc
uptak
activ
passiv
target
cell
brewer
alexand
conach
et
al
glycerol
mpg
base
niosom
also
consid
deliveri
dna
vaccin
mpgbase
niosom
incorpor
cation
surfact
dcchol
rather
anion
surfact
shown
offer
increas
stabil
increas
plasmid
dna
retent
presenc
competit
anion
compar
similarli
formul
pcbase
liposom
engend
transgenespecifi
c
immun
respons
compar
liposom
counterpart
obrenov
et
al
perri
et
al
perri
et
al
liposom
system
rang
immunostimulatori
agent
consid
design
niosom
vaccin
adjuv
exampl
mpgbase
vesicl
incorpor
dda
tdb
develop
vangala
et
al
result
increas
vesicl
size
due
hydrophil
surfact
without
alter
zeta
potenti
vesicl
compar
dda
tdb
vesicl
system
use
deliv
two
malari
antigen
merozoit
surfac
protein
glutam
rich
protein
glurp
mpgbase
vesicl
comparison
dda
liposom
gave
similarli
strong
humour
respons
analys
titr
howev
mpgbase
vesicl
also
show
high
titr
unlik
dda
tdb
system
vangala
et
al
modifi
cation
nonionicbas
vesicl
bile
acid
includ
formul
system
known
bilosom
develop
promot
oral
deliveri
vaccin
offer
protect
antigen
enzym
present
git
act
immunolog
adjuv
achiev
incorpor
bile
salt
sodium
deoxychol
formul
therebi
increas
stabil
carrier
thu
prevent
prematur
releas
antigen
via
oral
rout
propos
incorpor
bile
salt
vesicl
offer
resist
degrad
disrupt
digest
enzym
therefor
make
formul
stabl
schubert
et
al
studi
use
bilosom
incorpor
sever
antigen
proven
success
variou
anim
model
eg
apanama
mann
et
al
tetanu
toxoid
mann
et
al
hepat
b
shukla
et
al
virosom
term
gener
structur
attribut
resembl
liposom
system
often
consid
within
gener
area
liposom
unilamellar
vesicl
mean
diamet
nm
built
phospholipid
addit
virosom
incorpor
function
viral
envelop
glycoprotein
infl
uenza
haemagglutinin
promot
heamaglutininreceptor
bind
cell
fusion
immunostimul
variat
liposom
system
discuss
current
virosom
develop
clinic
product
two
exampl
virosomebas
vaccin
epax
infl
exal
tabl
licens
countri
clinic
use
immunestimul
complex
particl
iscom
initi
describ
morein
et
al
novel
structur
facilit
antigen
present
membran
protein
iscom
cagelik
particl
approxim
nm
size
incorpor
protein
antigen
hydrophob
interact
due
particul
natur
myschik
et
al
iscom
gener
consist
mixtur
quil
saponin
cholesterol
phospholipid
therefor
system
contain
lipid
structur
attribut
differ
liposom
addit
saponin
phosophipidcholesterol
mixtur
drive
chang
structur
nanosystem
iscom
also
prepar
offer
cation
charg
dccholesterol
replac
cholesterol
substitut
pc
dioleoyltrimethylammoniumpropan
cation
complex
form
similar
classic
anion
iscom
allow
divers
rang
antigen
use
formul
lendeman
et
al
see
refer
within
lendeman
et
al
oral
iscom
shown
promis
system
immun
respons
elicit
mhcrestrict
cytotox
tcell
respons
addit
local
induct
iga
mowat
et
al
result
introduct
immunostimulatori
agent
shown
use
enhanc
immun
respons
subunit
vaccin
offer
promis
platform
studi
solid
nanoparticl
also
extens
investig
potenti
vaccin
adjuv
like
vesicl
type
system
alreadi
describ
analogu
trehalos
tdm
consist
shorter
fatti
acid
chain
therefor
consid
less
toxic
davidsen
et
al
immunogen
coadjuv
elicit
protect
immun
tuberculosi
holtenandersen
et
al
davidsen
et
al
prepar
rang
size
choic
surfac
characterist
includ
select
immunomodul
polymer
nanoparticl
gener
formul
natur
synthet
polym
commonli
studi
polym
biodegrad
poli
lactidecoglycolid
plga
poli
lactic
acid
pla
poli
caprolacton
pcl
polysaccharid
particularli
chitosan
advantag
polym
well
characteris
use
rang
clinic
product
particularli
plga
altern
nanoparticl
prepar
solid
high
melt
point
lipid
dispers
aqueou
phase
exampl
lipid
use
includ
solid
triglycerid
satur
phospholipid
fatti
acid
well
toler
bodi
due
composit
sometim
describ
solidifi
ed
ow
emuls
oil
globul
replac
solidifi
ed
lipid
much
like
solid
polymer
nanoparticl
solid
lipid
nanoparticl
use
vaccin
adjuv
antigen
incorpor
within
lipid
matrix
particl
attach
lipid
nanoparticl
surfac
lipid
particl
normal
start
around
nm
size
prepar
largescal
homogenis
dispers
lipid
aqueou
environ
use
polymerbas
particul
vaccin
adjuv
strongli
investig
recent
work
refocus
investig
potenti
advantag
use
system
nano
rang
exampl
work
stano
et
al
demonstr
increas
size
polypropylen
sulphid
nanoparticl
nm
antigen
effect
deliv
mhc
class
mhc
class
iipresent
pathway
enhanc
target
nanoparticl
dendrit
cell
also
consid
eg
addit
recombin
fusion
protein
surfac
plga
nanoparticl
shown
promot
twofold
increas
dc
uptak
vitro
vivo
studi
demonstr
formul
promot
enhanc
antigenspecifi
c
igg
igg
subclass
higher
cytokin
respons
emulsionbas
system
fall
within
nanosci
defi
nition
use
consid
role
emuls
gener
vaccin
formul
fi
rst
emuls
adjuv
novarti
itali
licens
europ
infl
uenza
vaccin
fluad
ohagan
gregorio
oilinwat
ow
emuls
compos
squalen
natur
occur
oil
combin
surfact
sorbitan
trioleat
span
poli
oxyethylen
sorbitan
monool
tween
despit
concern
regard
safeti
due
occurr
autoimmun
dysfunct
rat
carlson
et
al
adjuv
establish
safeti
profi
le
human
goodhealth
immunocompromis
popul
black
et
al
donatoa
et
al
interest
note
fi
rst
emuls
licens
human
use
wellknown
experiment
adjuv
incomplet
freund
adjuv
icf
freund
et
al
use
human
infl
uenza
vaccin
chang
et
al
contrast
icf
water
oil
wo
emuls
compos
light
miner
oil
bayol
f
emulsifi
er
mannid
monool
aracel
combin
volum
ratio
lindblad
withdrawn
human
use
due
occasion
seriou
local
reaction
remain
experiment
goldstandard
adjuv
immunis
protocol
success
attribut
render
solubl
antigen
particul
form
improv
cell
recruit
inject
site
antigen
uptak
transport
local
lymph
node
mosca
et
al
similar
aluminium
salt
direct
activ
dendrit
cell
note
although
improv
traffi
cking
antigen
uptak
macrophag
dc
respect
note
express
solubl
activ
factor
may
inde
lead
indirect
dc
activ
mosca
et
al
term
potenti
advantag
solid
nanoparticl
bilay
type
system
direct
comparison
made
diffi
cult
control
number
differ
paramet
system
similarli
littl
work
undertaken
understand
impact
rout
administr
adjuv
type
strength
immun
respons
promot
howev
recent
multicentr
studi
differ
immun
respons
gener
mice
vaccin
subcutan
intraderm
intramuscular
intralymphat
rout
consid
ovalbuminload
liposom
n
trimethyl
chitosan
tmc
nanoparticl
poli
lactidecoglycolid
plga
microparticl
without
specifi
calli
select
immunerespons
modifi
er
directli
compar
mohanan
et
al
interestingli
neither
rout
administr
presenc
immunomodul
within
formul
made
notabl
differ
induc
antibodi
respons
howev
administr
rout
strong
impact
kinet
magnitud
respons
singl
intralymphat
administr
evalu
vaccin
formul
liposom
nanoparticl
microspher
gener
strong
respons
wherea
subcutant
adjuv
nanoparticl
abl
promot
notabl
respons
intraderm
intramuscular
rout
gener
intermedi
respons
mohanan
et
al
benefi
intralymphat
administr
rout
elicit
respons
confi
rmed
term
ifngamma
product
studi
demonstr
associ
immun
respons
sensit
rout
administr
wherea
respons
associ
immun
respons
rel
insensit
administr
rout
particul
deliveri
system
therefor
consider
vaccin
formul
combin
rout
administr
consid
plan
interpret
preclin
research
develop
vaccin
deliveri
system
given
rang
clinic
approv
nanotechnologybas
pharmaceut
product
alreadi
avail
interest
note
current
virosom
vaccin
epax
infl
exal
v
crucel
clinic
approv
use
howev
desir
characterist
nanosystembas
vaccin
adjuv
fulli
elucid
diffi
cult
identifi
key
attribut
focus
fi
nal
vivo
perform
lengthi
expens
marker
reli
similarli
continu
issu
regard
regul
exampl
stipul
liposom
adjuv
must
licens
vaccin
formul
adjuv
could
combin
variou
antigen
postlicens
add
complic
develop
licens
process
howev
progress
continu
cation
nanosystem
dda
tdb
formul
develop
staten
serum
institut
cation
adjuv
intracel
austria
overal
liposom
offer
strong
potenti
vaccin
adjuv
combin
abil
deliv
antigen
correct
cell
also
appropri
interact
stimul
cell
progress
remain
limit
todat
new
advanc
understand
effect
vaccin
system
product
regul
liposom
costeffect
manner
enhanc
progress
clinic
set
identifi
variou
vaccin
type
current
clinic
avail
discuss
respect
advantag
disadvantag
answer
vaccin
divid
three
basic
group
live
vaccin
inactiv
vaccin
toxoid
subunit
system
live
attenu
vaccin
consist
live
microorgan
virus
mutat
reduc
abil
grow
human
cell
still
abl
infect
target
cell
infect
mild
replic
limit
vaccin
gener
give
good
protect
risk
revers
virul
type
vaccin
consid
safe
use
immunocompromis
individu
inactiv
vaccin
consist
microorgan
virus
abil
infecti
remov
retain
immunogen
term
advantag
tend
improv
safeti
profi
le
compar
continu
live
system
gener
less
effect
live
attenu
vaccin
usual
stimul
humour
immun
often
requir
booster
dose
third
group
consist
part
infecti
agent
excret
toxoid
subunit
protein
subunit
vaccin
initi
strong
immun
respons
use
small
part
organ
advantag
subunit
vaccin
good
safeti
profi
le
howev
immun
respons
induc
vaccin
shortliv
thu
sever
boost
requir
achiev
protect
describ
structur
attribut
virosom
discuss
use
exampl
abl
use
vaccin
answer
virosom
bilay
vesicl
around
nm
size
prepar
phospholipid
incorpor
function
viral
envelop
glycoprotein
infl
uenza
haemagglutinin
promot
heamaglutininreceptor
bind
cell
fusion
immunostimul
exampl
epax
virosom
vaccin
clinic
indic
hepat
immunis
incorpor
subunit
antigen
hepat
antigen
protect
extracellular
milieu
therebi
limit
antigen
breakdown
enzym
well
prevent
rapid
remov
small
compound
mp
ensur
antigen
carri
within
virosom
deliveri
system
appropri
immunolog
cell
subsequ
antigen
taken
cell
due
action
glycoprotein
